Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | PTGFR | P43088 | 1/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220051 | 0.89 | PTGER4 (0.62) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL5223034 | 0.87 | PTGER4 (0.74) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL5218823 | 0.87 | PTGER4 (0.84) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL5219916 | 0.85 | PTGER4 (0.67) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL5224178 | 0.81 | PTGER4 (0.80) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL1734793 | 0.80 | PTGER4 (0.70) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL1734974 | 0.79 | PTGER4 (0.71) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL5222179 | 0.76 | PTGER4 (0.82) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL5220940 | 0.75 | PTGER4 (0.61) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL5221211 | 0.75 | PTGER4 (0.87) | PTGER4TBXA2RPTGFRPTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351934-B1 | NAPHTHALENE DERIVATIVES WHICH BIND TO THE EP4 RECEPTOR | GLAXO GROUP LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-6924297-B2 | Naphathalene derivatives which bind to the EP4 receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040102508-A1 | Naphathalene derivatives which bind to the ep4 receptor | SMITHKLINE BEECHAM CORPORATION | 2004-05-27 | — | — | US | disclosed |
| EP-1351934-A1 | NAPHTHALENE DERIVATIVES WHICH BIND TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002050032-A1 | NAPHTHALENE DERIVATIVES WHICH BIND TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102508-A1 | Naphathalene derivatives which bind to the ep4 receptor | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885TBXA2R 71/4885PTGFR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.